foliküler lenfomali{dotless} ve küçük lenfositik lenfomali{dotless} hastalarda nötropenik olmayan enfeksiyon i{dotless}nsidansi{dotless}: Rituximab tedavisinin etkisi

IF 0.3 4区医学 Q4 ONCOLOGY

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi Pub Date : 2012-12-01 DOI:10.4999/UHOD.11035

Rezwan Islam, Mahbubur Rahman, M. A. H. Mian, Hilmi Ege, Douglas Reding, Abdus Shakoor, Hong Liang, Richard J. Mercier

{"title":"foliküler lenfomali{dotless} ve küçük lenfositik lenfomali{dotless} hastalarda nötropenik olmayan enfeksiyon i{dotless}nsidansi{dotless}: Rituximab tedavisinin etkisi","authors":"Rezwan Islam, Mahbubur Rahman, M. A. H. Mian, Hilmi Ege, Douglas Reding, Abdus Shakoor, Hong Liang, Richard J. Mercier","doi":"10.4999/UHOD.11035","DOIUrl":null,"url":null,"abstract":"Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with indolent and aggressive forms of non-Hodgkin’s lymphoma and has become part of the standard therapy for patients with B-cell malignancies. The study was designed to examine if rituximab increases the risk to develop non-neutropenic infection (NNI). Medical records of 202 patients diagnosed as follicular lymphoma or small lymphocytic lymphoma were reviewed. Negative binomial regression was used to estimate relative risk (RR) of NNI. Rituximab (n= 41) and non-rituximab (n= 161) groups had a total of 31.636 and 195.691 reviewed patient days, and recorded a total of 67 and 154 infections, respectively. Negative binomial regression analysis revealed significant effects for the treatment (rituximab vs. non-rituximab) and age (p< 0.01). The RRs of viral and bacterial NNI for rituximab group compared to nonrituximab group were 3.33 and 2.60, respectively; while the RRs for one year increment of age were 1.03 and 1.04, respectively. The time-to-first viral and bacterial NNI for rituximab group were significantly faster than non-rituximab group. Rituximab may increase the risk of NNI in patients with follicular lymphoma or small lymphocytic lymphoma.","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4999/UHOD.11035","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with indolent and aggressive forms of non-Hodgkin’s lymphoma and has become part of the standard therapy for patients with B-cell malignancies. The study was designed to examine if rituximab increases the risk to develop non-neutropenic infection (NNI). Medical records of 202 patients diagnosed as follicular lymphoma or small lymphocytic lymphoma were reviewed. Negative binomial regression was used to estimate relative risk (RR) of NNI. Rituximab (n= 41) and non-rituximab (n= 161) groups had a total of 31.636 and 195.691 reviewed patient days, and recorded a total of 67 and 154 infections, respectively. Negative binomial regression analysis revealed significant effects for the treatment (rituximab vs. non-rituximab) and age (p< 0.01). The RRs of viral and bacterial NNI for rituximab group compared to nonrituximab group were 3.33 and 2.60, respectively; while the RRs for one year increment of age were 1.03 and 1.04, respectively. The time-to-first viral and bacterial NNI for rituximab group were significantly faster than non-rituximab group. Rituximab may increase the risk of NNI in patients with follicular lymphoma or small lymphocytic lymphoma.

查看原文本刊更多论文

利妥昔单抗是一种抗cd20单克隆抗体，已被证明对惰性和侵袭性非霍奇金淋巴瘤患者有效，并已成为b细胞恶性肿瘤患者标准治疗的一部分。该研究旨在检查利妥昔单抗是否会增加发生非中性粒细胞减少感染(NNI)的风险。本文回顾了202例诊断为滤泡性淋巴瘤或小淋巴细胞淋巴瘤的病例。采用负二项回归估计NNI的相对危险度(RR)。利妥昔单抗组(n= 41)和非利妥昔单抗组(n= 161)共回顾了31.636和195.691个患者日，分别记录了67和154例感染。负二项回归分析显示治疗(利妥昔单抗与非利妥昔单抗)和年龄有显著影响(p< 0.01)。与非利妥昔单抗组相比，利妥昔单抗组病毒和细菌NNI的相对危险度分别为3.33和2.60;年龄增加1年的相对危险度分别为1.03和1.04。利妥昔单抗组首次出现病毒和细菌NNI的时间明显快于非利妥昔单抗组。利妥昔单抗可能增加滤泡性淋巴瘤或小淋巴细胞性淋巴瘤患者发生NNI的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi ONCOLOGY-

CiteScore

1.60

自引率

16.70%

发文量

审稿时长

>12 weeks

期刊介绍： Target of Publication is the public representation of new scientific results of fundamental, problem-oriented, and search scientific investigations; analytical articles and reviews by actual scientific problems of coal mining industry, short reports in the field of coal mining industry, including the results of work of scientific meetings, conferences, summit’s and congresses in the field of mining. The basic purpose of the journal is the promotion of innovative activity in the coal mining industry by highlighting and discussing the results of basic and applied research, the experience in applying results of innovation for the development of the Russian coal mining. The most important tasks of the journal are: the generalization of scientific and practical achievements of specialists in the field of coal mining industry, specializing in the implementation of promising basic and applied research and development of priorities of high technologies; the scientific concept of the publication; the publication of the latest achievements in the field of innovation in coal mining industry. The journal lays special emphasis on methodical elaborations, analytical investigations in the sphere of coal mining. Targets of Journal are in publication of new results of scientific investigations performed by scientists, post-graduate students, and doctoral candidates performed by from higher schools, Russian Academy of Sciences, other scientific organizations of Russia, CIS countries, and foreign universities